)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Nuvectis Pharma
Nuvectis Pharma (NVCT) investor relations material
Nuvectis Pharma Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary21 Aug, 2026
Company overview and business model
Focuses on developing precision medicines for oncology addressing unmet medical needs.
Pipeline includes NXP100 (Factor B inhibitor), NXP200 (BRAF inhibitor), and NXP900 (SRC/YES1 kinase inhibitor), all in advanced or clinical stages.
Holds exclusive worldwide rights (excluding China) for NXP100 and NXP200, and global rights for NXP900.
Incorporated in Delaware in 2020, rebranded in 2021, and headquartered in Fort Lee, NJ.
Financial performance and metrics
As of July 31, 2026, 32,614,066 shares of common stock were outstanding.
Historical net tangible book value as of June 30, 2026, was $0.34 per share; pro forma as adjusted after recent offerings would be $5.29 per share.
Immediate dilution to new investors in the ATM offering is estimated at $18.06 per share.
Use of proceeds and capital allocation
Proceeds will fund advancement of NXP100, NXP200, NXP900, hiring, capital expenditures, public company costs, and general corporate purposes.
May allocate funds to acquisitions or investments in complementary businesses, products, or technologies.
Management retains broad discretion over use of proceeds.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nuvectis Pharma
- Advancing late-stage precision therapies for complement diseases and cancer with strong clinical data.NVCT
Corporate presentation - Q2 2026 net loss was $7.0M; $115M raised in July extends cash runway into 1H 2029.NVCTQ2 2026
- Late-stage NXP100 and NXP200 in-licensed, expanding pipeline in complement and oncology.NVCTStatus update
- Director election and auditor ratification approved; full results to be filed with SEC.NVCTAGM 2026
- NXP900 demonstrates potent, selective SRC inhibition and promising safety in early clinical trials.NVCTH.C. Wainwright 4th Annual BioConnect Investor Conference
- NXP900 shows promise in overcoming resistance in solid tumors and NSCLC with strong early data.NVCTCorporate presentation
- Q1 2026 net loss was $6.1M as NXP900 clinical progress drove higher R&D and G&A costs.NVCTQ1 2026
- Vote on director election and auditor ratification at the June 2026 annual meeting.NVCTProxy filing
- NXP900’s oral regimen targets resistance and unmet needs in NSCLC with a novel, well-tolerated approach.NVCTKOL Event
Next Nuvectis Pharma earnings date
12th Annual Cantor Fitzgerald Global Healthcare Conference11 Sep, 2026
Nuvectis Pharma
Next Nuvectis Pharma earnings date
12th Annual Cantor Fitzgerald Global Healthcare Conference11 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage